Robert J. Ferrante, PhD
Affiliations: | Neurology, Pathology, & Psychiatry | Boston University, Boston, MA, United States |
Area:
http://www.biomedexperts.com/Profile.bme/395895/Robert_J_FerranteWebsite:
http://www.bu.edu/alzresearch/team/faculty/ferrante.htmlGoogle:
"Robert Ferrante"Bio:
http://www.bumc.bu.edu/busm-bns/faculty/
http://www.bu.edu/research/highlights/awards/honors-awards-2007/
Cross-listing: Neurotree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tourette C, Farina F, Vazquez-Manrique RP, et al. (2014) The Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicity. Plos Biology. 12: e1001895 |
| Tourette C, Farina F, Vazquez-Manrique R, et al. (2014) B19 The Wnt Receptor Ryk Reduces Neuronal Resistance Capacity By Repressing Foxo Activity During The Early Phases Of Huntingtin Pathogenicity Journal of Neurology, Neurosurgery & Psychiatry. 85: A15-A15 |
| Thomas B, Matson S, Chopra V, et al. (2013) A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease. Analytical Biochemistry. 436: 112-20 |
| Taylor DM, Moser R, Régulier E, et al. (2013) MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 2313-25 |
| Wright PD, Wightman N, Huang M, et al. (2012) A high-throughput screen to identify inhibitors of SOD1 transcription. Frontiers in Bioscience (Elite Edition). 4: 2801-8 |
| Wang X, Sirianni A, Pei Z, et al. (2011) The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 14496-507 |
| Hu Y, Chopra V, Chopra R, et al. (2011) Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proceedings of the National Academy of Sciences of the United States of America. 108: 17141-6 |
| Xia G, Benmohamed R, Kim J, et al. (2011) Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. Journal of Medicinal Chemistry. 54: 2409-21 |
| Benmohamed R, Arvanites AC, Kim J, et al. (2011) Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group On Motor Neuron Diseases. 12: 87-96 |
| Kim J, Moody JP, Edgerly CK, et al. (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Human Molecular Genetics. 19: 3919-35 |